Why the study?
Giant cell myocarditis is rapidly progressive and potentially fatal, but detailed inflammatory responses remain unknown, particularly the formation of multinucleate giant cells.
Does inhibition of NETosis via PAD4 alleviate inflammation in giant cell myocarditis?
Does inhibition of NETosis via PAD4 alleviate inflammation in giant cell myocarditis?
Inhibition of NETosis via PAD4 may serve as a potential therapeutic target for alleviating inflammation in giant cell myocarditis.
Answers are grounded in this paper and cite their sources.
NETosis inhibition may offer a novel GCM therapy; leaves open confirmation in human disease.
Giant cell myocarditis (GCM) is a rare, usually rapidly progressive, and potentially fatal disease. Detailed inflammatory responses remain unknown, in particular the formation of multinucleate giant cells. We performed single-cell RNA sequencing analysis on 15,714 Cd45 + cells extracted from the hearts of GCM rats and normal rats. NETosis has been found to contribute to the GCM process. An inhibitor of NETosis, GSK484, alleviated GCM inflammation in vivo . MPO (a marker of neutrophils) and H3cit (a marker of NETosis) were expressed at higher levels in patients with GCM than in patients with DCM and healthy controls. Imaging mass cytometry analysis revealed that immune cell types within multinucleate giant cells included CD4 + T cells, CD8 + T cells, neutrophils, and macrophages but not B cells. We elucidated the role of NETosis in GCM pathogenesis, which may serve as a potential therapeutic target in the clinic.
No takes yet. Share an insight, caveat, or question.
Zhan et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: